Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

Mounsey, Ross BMustafa, SarahRobinson, LianneRoss, Ruth A.Riedel, GernotPertwee, Roger G.Teismann, Peter2015-08-062015-08-062015-11Mounsey, R B, Mustafa, S, Robinson, L, Ross, R A, Riedel, G, Pertwee, R G & Teismann, P 2015, 'Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease', Experimental Neurology, vol. 273, pp. 36-44. https://doi.org/10.1016/j.expneurol.2015.07.0240014-4886http://hdl.handle.net/2164/4787Date of Acceptance: 28/07/2015 The authors are grateful to the staff of the Medical Research Facility for their help with the animal care. This work was supported by the NHS Endowment fund 09/03 and the Wellcome Trust (WT080782MF). We thank Merck & Co. Inc., Rathway NJ, USA for the supply of DFU.91831427engEndocannabinoidsParkinson's diseaseMPTPNeuroprotectionCB1 cannabinoid receptorstoxicity in-vivomonoacylglycerol lipaseHuntingtons-Diseasecerebrospinal-fluidAlzheimers-Diseaseinduced neurotoxicityup-regulationfactor-alphabrainRC0321 Neuroscience. Biological psychiatry. NeuropsychiatryWellcome TrustRC0321Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's diseaseJournal article10.1016/j.expneurol.2015.07.024273